Wnt signalling is a relevant pathway contributing to amyloid Betapeptide-mediated neuropathology in alzheimer's disease

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 720-726

  da Cruz e Silva, Odete A B ^a   Henriques, Ana Gabriela ^a   Domingues, Sara Catarina Timóteo Santos ^a   da Cruz e Silva Silva, Edgar F ^a  

^a UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

Alzheime s disease; Phosphatases; Synaptic function; Wnt signalling

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA CATENIN; CYCLIC AMP; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; HUNTINGTIN; LITHIUM; MEVINOLIN; PRION PROTEIN; TAU PROTEIN; WNT PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; COMPETITIVE INHIBITION; COMPLEX FORMATION; DOPAMINERGIC NERVE CELL; FOREBRAIN; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; MOLECULAR DYNAMICS; NEOCORTEX; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NEUROBLASTOMA CELL; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SENILE PLAQUE; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION; SYNAPTOTOXICITY;

EID: 78649277730     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237458     Document Type: Article

References (76)

1. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol., 1991, 82(4), 239-259.
2. Lee, V.M.; Goedert, M.; Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci., 2001, 24, 1121-1159.
3. Mori, H.; Takio, K.; Ogawara, M.; Selkoe, D.J. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem., 1992, 267(24), 17082-17086.
4. Pike, C.J.; Overman, M.J.; Cotman, C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem., 1995, 270(41), 23895-23898.
5. Tekirian, T.L.; Saido, T.C.; Markesbery, W.R.; Russell, M.J.; Wekstein, D.R.; Patel, E.; Geddes, J.W. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J. Neuropathol. Exp. Neurol., 1998, 57(1), 76-94.
6. Rebelo, S.; Vieira, S.I.; Esselmann, H.; Wiltfang, J.; da Cruze Silva, E.F.; da Cruze Silva, O.A. Tyr687 dependent APP endocytosis and Abeta production. J. Mol. Neurosci., 2007, 32(1), 1-8.
7. Rebelo, S.; Vieira, S.I.; Esselmann, H.; Wiltfang, J.; da Cruze Silva, E.F.; da Cruze Silva, O.A. Tyrosine 687 phosphorylated Alzheimer's amyloid precursor protein is retained intracellularly and exhibits a decreased turnover rate. Neurodegener. Dis., 2007, 4(2-3), 78-87.
8. Henriques, A.G.; Vieira, S.I.; Crespo-Lopez, M.E.; Guiomar de Oliveira, M.A.; da Cruz e Silva, E.F.; da Cruz e Silva, O.A. Intracellular sAPP retention in response to Abeta is mapped to cytoskeleton-associated structures. J. Neurosci. Res., 2009, 87(6), 1449-1461.
9. Henriques, A.G.; Vieira, S.I.; da Cruze Silva, E.F.; da Cruze Silva, O.A. Alphabeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures. J. Mol. Neurosci., 2009, 39(1-2), 248-255.
10. Bowen, D.M.; Davison, A.N. Dementia in the elderly: biochemical aspects. J. R. Coll. Physicians Lond., 1984, 18(1), 25-27.
11. Davies, P.; Maloney, A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 1976, 2(8000), 1403.
12. Perry, R.H.; Candy, J.M.; Perry, E.K.; Irving, D.; Blessed, G.; Fairbairn, A.F.; Tomlinson, B.E. Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci. Lett., 1982, 33(3), 311-315.
13. Rubio, A.; Perez, M.; Avila, J. Acetylcholine receptors and tau phosphorylation. Curr. Mol. Med., 2006, 6(4), 423-428.
14. Wang, H.Y.; Li, W.; Benedetti, N.J.; Lee, D.H. Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J. Biol. Chem., 2003, 278(34), 31547-31553.
15. Vintem, A.P.; Henriques, A.G.; da Cruz, E.S.O.A.; da Cruz, E.S.E.F. PP1 inhibition by Abeta peptide as a potential pathological mechanism in Alzheimer's disease. Neurotoxicol. Teratol., 2009, 31(2), 85-88.
16. Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci., 2005, 22(8), 1942-1950.
17. Sun, L.; Liu, S.Y.; Zhou, X.W.; Wang, X.C.; Liu, R.; Wang, Q.; Wang, J.Z. Inhibition of protein phosphatase 2A and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience, 2003, 118(4), 1175-1182.
18. Knobloch, M.; Farinelli, M.; Konietzko, U.; Nitsch, R.M.; Mansuy, I.M. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J. Neurosci., 2007, 27(29), 7648-7653.
19. Dougherty, J.J.; Wu, J.; Nichols, R.A. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J. Neurosci., 2003, 23(17), 6740-6747.
20. Wu, J.; Khan, G.M.; Nichols, R.A. Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 * nicotinic receptors. Brain Res., 2007, 1182, 82-89.
21. Hamada, M.; Hendrick, J.P.; Ryan, G.R.; Kuroiwa, M.; Higashi, H.; Tanaka, M.; Nairn, A.C.; Greengard, P.; Nishi, A. Nicotine regulates DARPP-32(dopamine-and cAMP-regulated phosphoprotein of 32 kDa) phosphorylation at multiple sites in neostriatal neurons. J. Pharmacol. Exp. Ther., 2005, 315(2), 872-878.
22. Mattson, M.P. Pathways towards and away from Alzheimer's disease. Nature, 2004, 430(7000), 631-639.
23. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science, 2002, 298(5594), 789-791.
24. Heinitz, K.; Beck, M.; Schliebs, R.; Perez-Polo, J.R. Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56.B5.G4 cells. J. Neurochem., 2006, 98(6), 1930-1945.
25. Hsia, A.Y.; Masliah, E.; McConlogue, L.; Yu, G.Q.; Tatsuno, G.; Hu, K.; Kholodenko, D.; Malenka, R.C.; Nicoll, R.A.; Mucke, L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA, 1999, 96(6), 3228-3233.
26. Lue, L.F.; Kuo, Y.M.; Roher, A.E.; Brachova, L.; Shen, Y.; Sue, L.; Beach, T.; Kurth, J.H.; Rydel, R.E.; Rogers, J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol., 1999, 155(3), 853-862.
27. McLean, C.A.; Cherny, R.A.; Fraser, F.W.; Fuller, S.J.; Smith, M.J.; Beyreuther, K.; Bush, A.I.; Masters, C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol., 1999, 46(6), 860-866.
28. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci., 2007, 8(7), 499-509.
29. da Cruz e Silva, E.F.; da Cruze Silva, O.A.; Zaia, C.T.; Greengard, P. Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. Mol. Med., 1995, 1(5), 535-541.
30. Lee, M.S.; Kao, S.C.; Lemere, C.A.; Xia, W.; Tseng, H.C.; Zhou, Y.; Neve, R.; Ahlijanian, M.K.; Tsai, L.H. APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol., 2003, 163(1), 83-95.
31. da Cruz e Silva, O.A.; Fardilha, M.; Henriques, A.G.; Rebelo, S.; Vieira, S.; da Cruze Silva, E.F. Signal transduction therapeutics: relevance for Alzheimer's disease. J. Mol. Neurosci., 2004, 23(1-2), 123-142.
32. Rockenstein, E.; Torrance, M.; Adame, A.; Mante, M.; Ba-ron, P.;Rose, J.B.; Crews, L.; Masliah, E. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci., 2007, 27(8), 1981-1991.
33. Hu, M.; Waring, J.F.; Gopalakrishnan, M.; Li, J. Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells. J. Neurochem., 2008, 106(3), 1371-1377.
34. Liao, H.; Li, Y.; Brautigan, D.L.; Gundersen, G.G. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau. J. Biol. Chem., 1998, 273(34), 21901-21908.
35. Walsh, D.M.; Townsend, M.; Podlisny, M.B.; Shankar, G.M.; Fadeeva, J.V.; El Agnaf, O.; Hartley, D.M.; Selkoe, D.J. Certain inhibitors of synthetic amyloid beta-peptide(Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci., 2005, 25(10), 2455-2462.
36. Girault, J.A.; Greengard, P. The neurobiology of dopamine signaling. Arch. Neurol., 2004, 61(5), 641-644.
37. Arnsten, A.F.; Li, B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry, 2005, 57(11), 1377-1384.
38. Avila, J.; Perez, M.; Lucas, J.J.; Gomez-Ramos, A.; Santa Maria, I.; Moreno, F.; Smith, M.; Perry, G.; Hernandez, F. Assembly in vitro of tau protein and its implications in Alzheimer's disease. Curr. Alzheimer Res., 2004, 1(2), 97-101.
39. Novak, M.; Jakes, R.; Edwards, P.C.; Milstein, C.; Wischik, C.M. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc. Natl. Acad. Sci. USA, 1991, 88(13), 5837-5841.
40. Feijoo, C.; Campbell, D.G.; Jakes, R.; Goedert, M.; Cuenda, A. Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. J. Cell Sci., 2005, 118(Pt 2), 397-408.
41. Henriques, A.G.; Vieira, S.I.; da Cruz, E.S.E.F.; da Cruz, E.S.O.A. Abeta promotes Alzheimer's disease-like cytoskeleton abnormalities with consequences to APP processing in neurons. J. Neurochem., 2010, 113(3), 761-771.
42. Bamburg, J.R.; Wiggan, O.P. ADF/cofilin and actin dynamics in disease. Trends Cell Biol., 2002, 12(12), 598-605.
43. Kelly, B.L.; Ferreira, A. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience, 2007, 147(1), 60-70.
44. Boonen, R.A.; van Tijn, P.; Zivkovic, D. Wnt signaling in Alzheimer's disease: up or down, that is the question. Ageing Res. Rev., 2009, 8(2), 71-82.
45. Strutt, D. Frizzled signalling and cell polarisation in Drosophila and vertebrates. Development, 2003, 130(19), 4501-4513.
46. Toledo, E.M.; Colombres, M.; Inestrosa, N.C. Wnt signaling in neuroprotection and stem cell differentiation. Prog. Neurobiol., 2008, 86(3), 281-296.
47. Widelitz, R. Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors, 2005, 23(2), 111-116.
48. The Wnt Homepage: http://www.stanford.edu/~rnusse/wntwindow. html (accessed November 26, 2009).
49. Speese, S.D.; Budnik, V. Wnts: up-and-coming at the synapse. Trends Neurosci., 2007, 30(6), 268-275.
50. Kuhl, M.; Sheldahl, L.C.; Malbon, C.C.; Moon, R.T. Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J. Biol. Chem., 2000, 275(17), 12701-12711.
51. Sheldahl, L.C.; Park, M.; Malbon, C.C.; Moon, R.T. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr. Biol., 1999, 9(13), 695-698.
52. Torres, M.A.; Yang-Snyder, J.A.; Purcell, S.M.; DeMarais, A.A.; McGrew, L.L.; Moon, R.T. Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J. Cell Biol., 1996, 133(5), 1123-1137.
53. Ishitani, T.; Kishida, S.; Hyodo-Miura, J.; Ueno, N.; Yasuda, J.; Waterman, M.; Shibuya, H.; Moon, R.T.; Ninomiya-Tsuji, J.; Matsumoto, K. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol. Cell Biol., 2003, 23(1), 131-139.
54. Ciani, L.; Salinas, P.C. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat. Rev. Neurosci., 2005, 6(5), 351-362.
55. Asuni, A.A.; Hooper, C.; Reynolds, C.H.; Lovestone, S.; Anderton, B.H.; Killick, R. GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur. J. Neurosci., 2006, 24(12), 3387-3392.
56. Caricasole, A.; Copani, A.; Caraci, F.; Aronica, E.; Rozemuller, A.J.; Caruso, A.; Storto, M.; Gaviraghi, G.; Terstappen, G.C.; Nicoletti, F. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci., 2004, 24(26), 6021-6027.
57. Scali, C.; Caraci, F.; Gianfriddo, M.; Diodato, E.; Roncarati, R.; Pollio, G.; Gaviraghi, G.; Copani, A.; Nicoletti, F.; Terstappen, G.C.; Caricasole, A. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol. Dis., 2006, 24(2), 254-265.
58. Blalock, E.M.; Geddes, J.W.; Chen, K.C.; Porter, N.M.; Markesbery, W.R.; Landfield, P.W. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. USA, 2004, 101(7), 2173-2178.
59. Magdesian, M.H.; Carvalho, M.M.; Mendes, F.A.; Saraiva, L.M.; Juliano, M.A.; Juliano, L.; Garcia-Abreu, J.; Ferreira, S.T. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J. Biol. Chem., 2008, 283(14), 9359-9368.
60. Logan, C.Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol., 2004, 20, 781-810.
61. Alvarez, A.R.; Godoy, J.A.; Mullendorff, K.; Olivares, G.H.; Bronfman, M.; Inestrosa, N.C. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp. Cell Res., 2004, 297(1), 186-196.
62. Farias, G.G.; Godoy, J.A.; Vazquez, M.C.; Adani, R.; Meshulam, H.; Avila, J.; Amitai, G.; Inestrosa, N.C. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol. Dis., 2005, 18(1), 176-183.
63. Salins, P.; Shawesh, S.; He, Y.; Dibrov, A.; Kashour, T.; Arthur, G.; Amara, F. Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci. Lett., 2007, 412(3), 211-216.
64. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102(19), 6990-6995.
65. Su, Y.; Ryder, J.; Li, B.; Wu, X.; Fox, N.; Solenberg, P.; Brune, K.; Paul, S.; Zhou, Y.; Liu, F.; Ni, B. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry, 2004, 43(22), 6899-6908.
66. Phiel, C.J.; Wilson, C.A.; Lee, V.M.; Klein, P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 2003, 423(6938), 435-439.
67. Caccamo, A.; Oddo, S.; Tran, L.X.; LaFerla, F.M. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol., 2007, 170(5), 1669-1675.
68. Selenica, M.L.; Jensen, H.S.; Larsen, A.K.; Pedersen, M.L.; Helboe, L.; Leist, M.; Lotharius, J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol., 2007, 152(6), 959-979.
69. Yang, T.; Knowles, J.K.; Lu, Q.; Zhang, H.; Arancio, O.; Moore, L.A.; Chang, T.; Wang, Q.; Andreasson, K.; Rajadas, J.; Fuller, G.G.; Xie, Y.; Massa, S.M.; Longo, F.M. Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One, 2008, 3(11), e3604.
70. Caccamo, A.; Oddo, S.; Billings, L.M.; Green, K.N.; Martinez-Coria, H.; Fisher, A.; LaFerla, F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron, 2006, 49(5), 671-682.
71. Geula, C.; Mesulam, M.M. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis. Assoc. Disord., 1995, 9(Suppl 2), 23-28.
72. Geula, C.; Mesulam, M.M.; Saroff, D.M.; Wu, C.K. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J. Neuropathol. Exp. Neurol., 1998, 57(1), 63-75.
73. Alvarez, A.; Alarcon, R.; Opazo, C.; Campos, E.O.; Munoz, F.J.; Calderon, F.H.; Dajas, F.; Gentry, M.K.; Doctor, B.P.; De Mello, F.G.; Inestrosa, N.C. Stable complexes involving acetylcholines-terase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci., 1998, 18(9), 3213-3223.
74. Inestrosa, N.C.; Alvarez, A.; Perez, C.A.; Moreno, R.D.; Vicente, M.; Linker, C.; Casanueva, O.I.; Soto, C.; Garrido, J. Acetylcholi-nesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16(4), 881-891.
75. Reyes, A.E.; Chacon, M.A.; Dinamarca, M.C.; Cerpa, W.; Morgan, C.; Inestrosa, N.C. Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am. J. Pathol., 2004, 164(6), 2163-2174.
76. Inestrosa, N.C.; Urra, S.; Colombres, M. Acetylcholinesterase (AChE)--amyloid-beta-peptide complexes in Alzheimer's disease: the Wnt signaling pathway. Curr. Alzheimer Res., 2004, 1(4), 249-254.